Furthermore, statistically significant improvements in nocturnal arousals with ON-SXB vs placebo were observed in participants with NT2 at week 8 (7.5 g; –37.8 [4.4] vs –21.1 [4.8]; LSM difference vs placebo, p < .05) and week 13 (9 g; –45.0 [5.4] vs –24.6 [5.7]; LSM difference vs placebo, p < .05), but the reduction did not reach statistical significance at week 3 [6 g; –31.9 [4.3] vs –26.1 [4.6]).
← all excerpts
Efficacy of once-nightly sodium oxybate (FT218) in narcolepsy type 1 and type 2: post hoc analysis from the Phase 3 REST-ON Trial.
1
—
—